Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 16 January 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Predicting safety and success of reinitiation of infliximab therapy

Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy, reports the latest issue of the Clinical Gastroenterology & Hepatology.

News image

fiogf49gjkf04

Few agents are available for the treatment of inflammatory bowel diseases, and patients frequently become unresponsive to biologics.

Dr Filip Baert and colleagues from Belgium investigated the feasibility of reinitiating infliximab therapy for patients who previously received only episodic therapy with, lost response to, or had infusion reactions to infliximab.

The researchers identified factors associated with the success and safety of restarting infliximab, such as antibodies to infliximab and trough levels of the drug.

From the inflammatory bowel disease biobank, the team identified 128 consecutive patients who restarted infliximab after a median 15-month discontinuation.

The researchers also analyzed serum samples that had been collected during the first period of infliximab therapy, when therapy was reinitiated, and at later time points for trough levels and antibodies to infliximab.

15 patients had acute infusion reactions
Clinical Gastroenterology & Hepatology

The team investigated correlations among response to treatment, infusion reactions, treatment modalities, trough levels, and antibodies to infliximab.

Reinitiation of infliximab therapy produced a response in 84.5% of patients at week 14, 70% of patients at 1 year, and in 61% of patients at more than 4 years.

The research team found that 15 patients had acute infusion reactions, and 10 patients had delayed infusion reactions.

The absence of antibodies to infliximab at T+1 and reinitiation with concomitant immunomodulator therapy were associated with short-term responses.

The team noted that pregnancy or remission as reason for discontinuation, and higher trough levels at T+1 were associated with long-term response.

Undetectable antibodies to infliximab at T+1 were associated with the safety of reinitiating therapy HR for infusion reaction with detectable antibodies to infliximab.

Dr Baert's team concludes, "Reinitiating infliximab therapy can be safe and effective for patients with Crohn's disease or ulcerative colitis after a median 15-month discontinuation period."

Clin Gastroenterol Hepatol 2014: 12(9): 1474–1481.e2
03 September 2014

Go to top of page Email this page Email this page to a colleague

 16 January 2017 
Sarcopenia and severe liver fibrosis
 16 January 2017 
HCV eradication in cirrhosis
 16 January 2017 
Thyroid and primary biliary cholangitis
 13 January 2017 
Anti-TNF discontinuation in patients with IBD
 13 January 2017 
Isolated colonic Crohn's disease
 13 January 2017 
Early monocytopenia in paracetamol-induced liver failure
 12 January 2017 
Internet-delivered therapy for adolescents with IBS
 12 January 2017 
NAFLD and coronary artery calcium score
 12 January 2017 
Providing relief for chronic constipation
 11 January 2017 
Fatigue in IBD
 11 January 2017 
Pancreatic cancer risk with asthma and nasal allergies
 11 January 2017 
PPIs and bone strength and structure
 10 January 2017 
Colorectal cancer risk in serrated polyposis syndrome
 10 January 2017 
Evaluation of abnormal liver chemistries
 10 January 2017 
Pelvic physiotherapy in functional constipation
 09 January 2017 
Intestinal microbiota and IBS
 09 January 2017 
Helicobacter and Campylobacter in IBD
 09 January 2017 
Diagnosis of microscopic colitis
 06 January 2017 
Recommendations on colorectal cancer screening 
 06 January 2017 
Colorectal cancer susceptibility gene variants
 06 January 2017 
Thiopurine-induced hepatotoxicity in IBD
 05 January 2017 
Histological index for ulcerative colitis
 05 January 2017 
Crohn's disease after total colectomy with permanent ileostomy
 05 January 2017 
Celiac disease screening in IBS
 04 January 2017 
Serrated colorectal polyps risk factors
 04 January 2017 
Score to predict eosinophilic esophagitis
 04 January 2017 
Platelet transfusion for gastrointestinal bleeding
 03 January 2017 
Pelvic physiotherapy for functional constipation in children
 03 January 2017 
Tumor necrosis factor antagonists in IBD
 03 January 2017 
Mesenchymal stromal cell therapy for IBD
 22 December 2016 
Happy holidays!
 21 December 2016 
Pharmacotherapy for NAFLD
 21 December 2016 
Predicting disease activity in eosinophilic esophagitis
 21 December 2016 
Breath Testing for Barrett’s esophagus
 20 December 2016 
H. pylori on the ethnic distribution of Barrett's metaplasia
 20 December 2016 
Prognostic biomarker in colorectal cancer
 20 December 2016 
Online health information for colorectal cancer screening
 19 December 2016 
Risk of tuberculosis in IBD
 19 December 2016 
Risk of complications of percutaneous liver biopsy
 19 December 2016 
Hospital research and colorectal cancer survival
 16 December 2016 
Predicting organ failure in acute pancreatitis
 16 December 2016 
Non-invasive genomic biomarkers for colorectal cancer
 16 December 2016 
Mortality rates for major causes of death
 15 December 2016 
Adjuvant chemotherapy use varies for advance colon cancer
 15 December 2016 
Histological index for ulcerative colitis
 15 December 2016 
Readmission after acute upper GI bleed
 14 December 2016 
Management of H. pylori infection
 14 December 2016 
Fecal microbiota transfer
 14 December 2016 
Colorectal cancer screening in primary care
 13 December 2016 
Caffeine and hepatitis C virus infection
 13 December 2016 
Features of asymptomatic erosive esophagitis
 13 December 2016 
Clinical relapse among patients with ulcerative colitis
 12 December 2016 
Drug-induced liver injury 
 12 December 2016 
Colorectal cancer prevention
 12 December 2016 
Precision medicine in IBD
 09 December 2016 
Use of GI alarm features for colorectal cancer diagnosis
 09 December 2016 
Emergency department use by IBD patients
 09 December 2016 
PPI regimens for upper GI bleeds
 08 December 2016 
Preterm birth in women with IBD
 08 December 2016 
Precision medicine in IBD

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us